Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,046 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guidelines on the diagnosis and investigation of AL amyloidosis.
Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ, Hawkins PN, Pratt G; BCSH Committee. Gillmore JD, et al. Among authors: hawkins s, hawkins pn. Br J Haematol. 2015 Jan;168(2):207-18. doi: 10.1111/bjh.13156. Epub 2014 Oct 14. Br J Haematol. 2015. PMID: 25312307 Free article. No abstract available.
Guidelines on the management of AL amyloidosis.
Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ, Hawkins PN, Pratt G; BCSH Committee. Wechalekar AD, et al. Among authors: hawkins s, hawkins pn. Br J Haematol. 2015 Jan;168(2):186-206. doi: 10.1111/bjh.13155. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25303672 Free article. No abstract available.
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
Ravichandran S, Mahmood S, Wisniowski B, Sachchithanantham S, Popat R, Lachmann H, Rabin N, Ramasamy K, Hawkins S, Kyriakou C, Gillmore J, Yong K, Hawkins P, Jackson G, Pratt G, D Wechalekar A. Ravichandran S, et al. Among authors: hawkins s, hawkins p. Br J Haematol. 2022 Jul;198(2):328-332. doi: 10.1111/bjh.18216. Epub 2022 May 4. Br J Haematol. 2022. PMID: 35509237
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Yong KL, Hinsley S, Auner HW, Bygrave C, Kaiser MF, Ramasamy K, De Tute RM, Sherratt D, Flanagan L, Garg M, Hawkins S, Williams C, Cavenagh J, Rabin NK, Croft J, Morgan G, Davies F, Owen RG, Brown SR. Yong KL, et al. Among authors: hawkins s. Haematologica. 2021 Oct 1;106(10):2694-2706. doi: 10.3324/haematol.2021.278399. Haematologica. 2021. PMID: 33910333 Free PMC article. Clinical Trial.
1,046 results